OM
CGON icon

Opaleye Management’s CG Oncology CGON Stock Holding History

Opaleye Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.42M Sell
94,800
-315,200
-77% -$17.9M 0.85% 27
2025
Q4 		$17M Hold
410,000
– – 2.25% 10
2025
Q3 		$16.5M Buy
410,000
+144,000
+54% +$4.19M 2.33% 10
2025
Q2 		$6.92M Buy
266,000
+102,012
+62% +$2.46M 1.4% 15
2025
Q1 		$4.02M Buy
+163,988
New +$4.61M 0.89% 25

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Opaleye Management's CGON Position: Q1 2026 in Review

Opaleye Management reduced its CG Oncology (CGON) stake by 77% in Q1 2026, selling an estimated $17.9M and leaving 94,800 shares worth $6.42M. The position accounts for 0.85% of the portfolio, ranked #27.

Opaleye Management first reported a position in CGON in Q1 2025 and has held it in 5 quarters since. The position peaked at $17M in Q4 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Opaleye Management held 94,800 shares of CG Oncology worth $6.42M as of Q1 2026.
  • Opaleye Management sold 315,200 CG Oncology shares in Q1 2026, an estimated $17.9M.
  • CG Oncology made up 0.85% of Opaleye Management's portfolio in Q1 2026, its #27 holding.
  • Opaleye Management first reported a position in CG Oncology in Q1 2025 and has held it in 5 quarters since.
  • Opaleye Management's CG Oncology position peaked at $17M in Q4 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.